SRPT

SEC Filing Summary: AVI BioPharma, Inc. (10-Q)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2002. The registrant is AVI BioPharma, Inc., a development-stage biopharmaceutical company based in Portland, Oregon. The company has been unprofitable since its inception in 1980 and derives no material revenue from product sales. Its primary activities involve research and development (R&D), specifically focusing on technologies for Phase III clinical trials and potential commercial launch of the Resten-NG product.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Q3 2002 revenue decreased 24% compared to Q3 2001, primarily due to lower grant revenues. However, for the nine-month period, revenue increased 62% year-over-year, driven by higher research contract revenues.
• Operating Expenses: Total operating expenses increased significantly. R&D expenses rose by 65% in Q3 2002 and 121% for the nine-month period. This increase is largely attributed to outside contractor GMP manufacturing costs for NEUGENES for Phase III trials and the Resten-NG product launch.
• Investment Impairment: The company recorded a non-cash write-down of $1,791,304 in Q3 2002 (and $4,478,260 for the nine months) related to an "other than temporary impairment" of its investment in SuperGen, Inc. This contrasts with a $12.5 million write-down in the same period in 2001.
• Liquidity: Cash and short-term securities decreased from $25.6 million at year-end 2001 to $22.5 million at September 30, 2002. This reduction was offset by a private equity financing in March 2002 that raised approximately $21.3 million in net proceeds.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue incurring losses for the foreseeable future. There are no expected material revenues from product sales for at least the next 12 months.
• Expenditure Guidance: Estimated operating expenditures for 2002 are approximately $25 million, an increase from the earlier estimate of $20 million due to higher-than-expected manufacturing costs. Expenditures for 2003 are expected to be less than or equal to the 2002 estimate.
• Liquidity Strategy: The company expects existing cash resources to satisfy requirements for the next 12 months. However, absent new product revenues or partnerships, it may need to raise additional capital through private or public offerings, which could be dilutive.
• Risks: Key risks include the success of R&D and clinical trials, regulatory approvals (FDA), competitive products, and the ability to secure future financing. The company has no credit facility.
• Unusual Items: A $500,000 loan was made to the CEO in June 2002, secured by his stock. This loan is grandfathered under the Sarbanes-Oxley Act as it was made prior to the Act's prohibition on executive loans.

Investor Verification Checklist

• Verify the status and timeline of the Phase III clinical trials for NEUGENES and the Resten-NG product, as these drive current high operating costs.
• Confirm the fair market value and impairment status of the SuperGen, Inc. investment, which has seen significant write-downs.
• Monitor the company's cash burn rate against the revised $25 million 2002 expenditure estimate to assess the need for near-term capital raises.
• Review the terms of the $500,000 related-party loan to the CEO and its impact on corporate governance compliance.
• Assess the progress of moving NEUGENES manufacturing in-house to the new GMP facility to reduce future outside contractor costs.